End-to-End Digital Transformation in the Pharmaceutical Industry: A Sequential Mixed-Methods Analysis of Industry Priorities and Implementation Barriers. (Preprint)

BACKGROUND The pharmaceutical industry faces unprecedented challenges including declining drug approval rates, plummeting R&D returns [1, 2], and escalating protocol complexity. Digital transformation represents the most promising end-to-end approach for addressing these challenges, yet limited understanding exists regarding industry-wide priorities and implementation barriers. OBJECTIVE This study aimed to identify digital transformation priorities across diverse pharmaceutical industry stakeholders and explore the specific barriers preventing successful implementation through a collaborative, mixed-methods approach. METHODS We employed a sequential mixed-methods design with three phases: (1) WS1 (Denmark) with 47 participants randomly divided into 3 working groups, all discussing three main theme areas and generating 110 digital transformation topics; (2) Follow-up survey with 55.3% response rate (26/47 participants) validating topic priorities across all three theme areas; and (3) WS2 with expert keynote and panel discussions exploring implementation challenges. Data sources included workshop outputs, survey responses, and transcribed panel discussions. Analysis involved thematic coding, convergence analysis, and tension identification. RESULTS Analysis revealed 19 common categories across all working groups despite the 3 diverse starting themes. WS1 produced 7 consolidated categories for Theme 1 (desired outcomes), 5 for Theme 2 (pathways), and 7 for Theme 3 (measurement), totaling 19 consolidated categories. These were further refined into 17 survey topics (8+4+5) through post-workshop consolidation. The survey confirmed strong consensus with 55.3% response rate (26/47 participants). WS2 identified 5 key implementation tensions: innovation speed vs. safety standards, collaboration vs. competition, technology vs. change management, patient preferences vs. operational efficiency, and data democratization vs. privacy protection. Panel discussions provided deep insights into implementation challenges and solutions. Results obtained support exploratory generalization across comparable settings and do not establish causal effects. CONCLUSIONS The pharmaceutical industry demonstrates strong consensus on patient-centric digital transformation priorities as seen across the value chain, with universal recognition of the need for pre-competitive collaboration. However, significant implementation barriers exist beyond technology, requiring integrated approaches to organizational change, regulatory innovation, and industry-wide standards development. Panel discussions and expert insights provide a pathway for continued collaboration and knowledge sharing. Incremental approach to sharing of industry-wide knowledge is further recommended. CLINICALTRIAL This study is not a clinical trial.